Type 2 diabetes (T2D) is a chronic, progressive disease that frequently necessitates treatment with basal insulin to maintain adequate glycaemic control.1, 2 In an ageing population with increasing longevity, the global burden of diabetes in individuals 65 years of age or older is projected to increase from 122.8 million in 2017 to 253.4 million in 2045.3 Here, INS is linked to type 2 diabetes mellitus.